<?xml version="1.0" encoding="UTF-8"?>
<p id="Par51">Bacterial lysates have recently been proved to reduce the number of the recurrent wheezing episodes and asthma episodes, in patients treated with BL compared with placebo (5 trials) [
 <xref ref-type="bibr" rid="CR91">91</xref>]. However, higher-quality trials are required before firm conclusions can be drawn regarding the prophylactic efficacy of bacterial lysates in asthma. A new large scale trial, currently carried out in the USA (ORal Bacterial EXtracts for the prevention of wheezing lower respiratory tract illness, ORBEX, NCT02148796; 
 <italic>N</italic> = 1000) will address these concerns, but its results are expected in 2022.
</p>
